The U.S. labor market showed further signs of cooling in November as nonfarm payrolls rose by 64,000, only modestly above expectations but still weak by historical standards, while the unemployment rate unexpectedly climbed to 4.6%,The Dow Jones Industrial Average fell 0.6% to 48,114.26, while the S&P 500 dropped 0.2% to 6,800.26. The Nasdaq rose 0.2% to 23,111.46.These are the top stocks that gained the attention of retail traders and investors through the day.Tilray Brands Inc. (NASDAQ:TLRY) Tilray Brands ...

The U.S. Food and Drug Administration has approved GSK's add-on drug to treat asthma and a chronic inflammatory sinus condition, the drugmaker said on Tuesday, paving the way for a less frequently dosed treatment option for patients to enter the market. ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Group 1 - The core viewpoint of the news is the establishment of a full industrial chain cooperation between Baiyu Chuanfa Tibetan Medicine Industry Co., Ltd. and leading domestic ethnic medicine enterprises to promote the development of Tibetan medicine products and enhance local economic growth [1] - Baiyu Chuanfa Tibetan Medicine Industry Co., Ltd. is a newly established company under Sichuan Development (Holding) Company, focusing on high-quality development of the Tibetan medicine industry and creating the "Baiyu" brand [1] - The signing event is part of the provincial coordination mechanism's efforts to enhance the effectiveness of state-owned enterprise support for underdeveloped counties, as outlined in the "Seven Measures" document [1][2] Group 2 - The "Seven Measures" document aims to broaden cooperation channels between enterprises and accelerate the establishment of win-win platforms for state-owned enterprises and supported counties [2] - Sichuan Development (Holding) Company has established three subsidiaries in Baiyu County, including a Tibetan medicine company, a forestry company, and an enterprise service company, which provides one-stop solutions for various transactions [2] - The document also emphasizes the formation of a "matrix" support team of state-owned enterprises to enhance collaborative efforts in helping underdeveloped counties [2][3] Group 3 - Chengdu Yimin Group has formed a leadership team to conduct on-site research in the underdeveloped county of Rangtang, focusing on local agricultural and livestock products [3] - As of November 2023, state-owned enterprises have registered 113 companies in supported counties, with total investment exceeding 520 billion yuan and sales support surpassing 900 million yuan [3] - The provincial state-owned assets supervision and administration commission plans to further strengthen coordination and expand support efforts to achieve higher quality development in underdeveloped counties [3]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Telix Pharmaceuticals Ltd. securities during the specified Class Period of the upcoming lead plaintiff deadline for a securities class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Telix securities between February 21, 2025, and August 28, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by January 9, 2026 [3]. - The lawsuit alleges that defendants made materially false and misleading statements regarding Telix's progress in prostate cancer therapeutic candidates and the quality of its supply chain [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019 alone, and has been recognized as a leader in the field of securities class action settlements [4].

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

Core Insights - Monte Rosa Therapeutics Inc. has shared interim data from a Phase 1/2 clinical study evaluating MRT-2359 in combination with enzalutamide for patients with metastatic castration-resistant prostate cancer (mCRPC) [1] Study Population and Safety Profile - The study included 20 heavily pretreated individuals with advanced CRPC, all of whom were evaluable for safety [2][3] - The combination treatment maintained a favorable safety profile, with primarily mild to moderate gastrointestinal adverse events [3] Efficacy Results - Among 14 evaluable patients, there were two RECIST partial responses in the AR mutant subset, with a disease control rate of 100% in this group [4] - The overall disease control rate (DCR) was 64% (9 of 14) in the total evaluable population, with stable disease observed in patients with wild-type AR or ARV7 transcripts [4] Future Plans - Monte Rosa plans to present updated data at the ASCO Genitourinary Cancers Symposium in February and initiate a Phase 2 study of MRT-2359 in combination with a second-generation AR inhibitor [5] - The upcoming Phase 2 study will assess efficacy in mCRPC patients with AR mutations and will evaluate various clinical endpoints, anticipated to start in 2026 [6] Additional Study Insights - The Phase 1/2 study also included six patients with hormone receptor-positive breast cancer, which showed a favorable safety profile but insufficient evidence of activity for further development in this population [7] - Monte Rosa plans to present interim Phase 1 data on MRT-8102 in early 2026, with ongoing studies assessing its safety and potential efficacy [8]

Core Insights - GLP-1 pills for obesity are expected to be available in the U.S. by 2026, providing a more convenient and potentially cheaper alternative to current injection treatments [1][2] - Drugmakers Novo Nordisk and Eli Lilly are developing daily pills aimed at expanding the patient base, particularly for those averse to needles or who do not perceive their condition as severe enough to warrant injections [2] - While the new pills may not be more effective than existing weekly injections, the introduction of these options is seen as a significant benefit for patients, especially following recent supply shortages of injections [3] Market Potential - Goldman Sachs analysts project that the new pills could capture a 24% market share, equating to approximately $22 billion, of the anticipated $95 billion global weight loss drug market by 2030 [4]

Core Viewpoint - Pfizer has lowered its FY2026 profit forecast due to declining Covid vaccine sales and impending patent expirations on key products, projecting profits between $2.80 and $3 per share, below analyst expectations of $3.05 per share [1] Financial Projections - The company anticipates FY2026 revenue to be between $59.5 billion and $62.5 billion, compared to analyst estimates of $61.59 billion [2] - Pfizer's FY2025 profit forecast has also been reduced to $62 billion, which is at the lower end of its previous guidance of $61 billion to $64 billion [6] Research and Development - R&D expenses are expected to range from $10.5 billion to $11.5 billion as Pfizer focuses on advancing its newly licensed PD-1xVEGF oncology asset and various clinical programs from the Metsera acquisition [3] Impact of Covid Vaccine Sales - Projected profits from Covid vaccine sales are expected to decline by $1.5 billion in 2026 compared to 2025 forecasts, reflecting a broader trend affecting other pharmaceutical companies [4] Patent Expirations - Pfizer estimates a loss of $1.5 billion in profit due to the expiration of market exclusivity for certain products, including the JAK inhibitor Xeljanz, blood thinner Eliquis, and cancer drug Ibrance [5] Cost-Cutting Measures - The company has initiated a cost-cutting strategy aimed at reducing spending by $7.7 billion by 2027, which includes cutting 230 jobs in Switzerland as part of a broader operational downsizing [7] Strategic Focus - Pfizer is targeting the weight loss market while implementing stringent cost-cutting measures and pursuing pipeline-enhancing deals [8]

Viking's pipeline may release its value next year, and larger companies are likely to consider acquiring it.Upstart biotech company Viking Therapeutics (VKTX 1.27%) is a potential takeover candidate in 2026. That's not a reason to buy the stock in itself, but does highlight the potential value in its product pipeline. Here's why major drugmakers might now be drawn to buying this relatively small player in the pharmaceutical industry.Takeover activity is high in the industryThe recent bidding war between Pfi ...